Praxis Precision Medicines, Inc. (PRAX)
| Market Cap | 956.40M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -110.59M |
| Shares Out | 41.57M |
| EPS (ttm) | -3.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,555 |
| Open | 21.68 |
| Previous Close | 21.72 |
| Day's Range | 20.54 - 22.26 |
| 52-Week Range | 12.71 - 60.95 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 53.25 (+142.7%) |
| Est. Earnings Date | Nov 15, 2021 |
About PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price forecast is 53.25, which is an increase of 142.71% from the latest price.
News
Praxis Precision Medicines To Provide Corporate Update And Report Third Quarter 2021 Financial Results On Wednesday, ...
BOSTON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for c...
Praxis Precision Medicines to Present at Citi's 16th Annual BioPharma Virtual Conference
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ther...
BofA Initiates Praxis Precision Medical At Buy
Praxis Precision Medicines Inc's (NASDAQ:PRAX) lead asset has demonstrated encouraging data for central nervous system diseases and has a broad pipeline that targets both prevalent and rare disorders, a...
Praxis Unveils Perimenopausal Depression Trial Data
Praxis Precision Medicines Inc (NASDAQ: PRAX) has reported results from its PRAX-114 Phase 2a Part B proof-of-concept trial for perimenopausal depression (PMD). PRAX-114 60 mg suspension formulation (n=...
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD)
Praxis Precision Medicines Reports PRAX-114 Perimenopausal Depression (PMD) Phase 2a Proof-of-Concept Trial Results a...
PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study
Praxis Precision Medicines to Present at 2021 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of thera...
Praxis Precision Medicines to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of thera...
Praxis Precision Medicines Prices Public Offering of Common Stock
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therap...
Praxis Precision Medicines Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therap...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results
Expands pipeline with new indications for PRAX-114 and PRAX-944
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
PRAX-562 Phase 2 clinical trial for treatment of DEEs expected to initiate in first half of 2022 PRAX-562 Phase 2 clinical trial for treatment of DEEs expected to initiate in first half of 2022
Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Cudkowicz, M.D.
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ther...
Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, ...
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ther...
Praxis Precision Medicines to Present at Stifel's 3rd Annual CNS Day
CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ther...
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of thera...
Praxis Precision Medicines Provides Update On PRAX-114 IND Submission For The Treatment Of Major Depressive Disorder
- Praxis expects to initiate Phase 2/3 clinical trial for PRAX-114 in MDD in 1H21 -
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. ...
NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ("Praxis" or the "Company") (NASDAQ: PRAX). Such investors are ad...
Praxis Precision Medicines Provides Regulatory Update On PRAX-114 Program
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of thera...
Praxis Precision Medicines Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Opt...
CAMBRIDGE, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of thera...
Praxis Precision Medicines Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of thera...
Praxis Precision Medicines upsizes IPO by 35%, now looks to raise up to $180 million
Praxis Precision Medicines Inc. has increased the number of shares it plans to sell in its initial public offering by 35%, as the Massachusetts-based biopharmaceutical company developing treatments for ...
Praxis Precision Medicines Readies $126 Million IPO
Praxis Precision Medicines has filed proposed terms for its U.S. IPO.